ID   HOE6V
AC   CVCL_4J71
DR   cancercelllines; CVCL_4J71
DR   Wikidata; Q54890125
RX   Patent=US8835164;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00218.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P03126; Human papillomavirus type 16 protein E6 (Note=Variant form).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
DI   NCIt; C180841; Human papillomavirus-independent cervical squamous cell carcinoma
DI   ORDO; Orphanet_213767; Squamous cell carcinoma of the cervix uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1094 ! C-33 A
SX   Female
AG   66Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 19-12-24; Version: 19
//
RX   Patent=US8835164;
RA   Rhee J.E., Jang D.H., Kim S.S., Choi B.S.;
RT   "Cell line stably expressing mutated oncoprotein E6 and method of
RT   screening anticancer compound of uterine cervical cancer using the
RT   same.";
RL   Patent number US8835164, 16-Sep-2014.
//